Shareholders Sue Amgen Over Anemia Drugs

Law360, New York (April 18, 2007, 12:00 AM EDT) -- Biotech company Amgen Inc. has been hit with a class action securities lawsuit alleging that the drug maker misled shareholders by concealing the results of a clinical study involving two of its anemia drugs.

The suit, filed Wednesday in the U.S. District Court for the Central District of California, alleges that Amgen failed to disclose the results of trials for anemia drugs Epogen and Aranesp.

Epogen and Aranesp have received the approval of the U.S. Food and Drug Administration to be prescribed to fight anemia in...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.